Innocan Pharma Corporation announced the company's latest findings. animals were injected every several weeks with LPT-CBD over a period of 6 months, and showed: Good tolerance of the drug. Consistently noticeable pain relief and increased mobility.

No undesirable adverse effects. Based on these findings, the Innocan research team, led by Prof. Chezy Barenholz, assumes that LPT-CBD can be safely used for long-term therapy. LPT-CBD was initially designed for the treatment of chronic diseases that require a continuous drug administration and therapeutic effect.

These data represent an interim supportive and encouraging results. Hints of safety, major impact on future development. After each injection, animals were closely monitored, and no adverse effects were observed, including no changes in vital signs, complete blood count and biochemistry panel taken at various times after injections.

results suggest that multiple LPT-CBD injections are safe. This outcome of liposomal CBD formulation's safety is a significant stride in future development trajectory. Significant progress toward safety assessment.

The safety of a drug is an important factor that is required to be carefully evaluated before moving to human trials. Typically, such safety assessment is initially performed in animals and later confirmed in humans. liposomal technology was specifically designed to provide a longer exposure to CBD when compared to the conventional oral route.ence, data strongly implies that a long CBD exposure is not only effective as previously announced but can also be well tolerated for a long period.